INDEMNITY AGREEMENTIndemnity Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 2015, is made by and between REGENXBIO Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (“Agreement”) is entered into as of March 21, 2014 (“Effective Date”) by and between ReGenX Biosciences, LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and AveXis, Inc. (formerly known as BioLife Cell Bank, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 4925 Greenville Avenue, Suite 604, Dallas, TX 75206 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
ContractEmployment Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Maryland
This Employment Agreement (this “Agreement”) is entered into as of June 30, 2015, by and between Vittal K. Vasista (the “Employee”) and REGENXBIO Inc., a Delaware corporation (the “Company”).
CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY of PENNSYLVANIA License AgreementLicense Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and ReGenX, LLC, a Delaware limited liability company (“Company”). This Agreement is being signed on February 20, 2009 (the “Execution Date”). This Agreement will be effective on February 24, 2009 (the “Effective Date”).
LICENSE AGREEMENTLicense Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This LICENSE AGREEMENT (“Agreement”) is entered into as of March 6, 2009 (“Effective Date”) by and between ReGenX, a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“ReGenX”) and SmithKline Beecham Corporation, a Pennsylvania corporation doing business as GlaxoSmithKline, with offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania, 19102 (“GSK”). ReGenX and GSK are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Delaware
This LICENSE AGREEMENT (“Agreement”) is entered into as of July 9th, 2013 (“Effective Date”) by and between ReGenX Biosciences, LLC (formerly known as ReGenX, LLC), a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at ****, San Francisco, California, 94115 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 1st, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 15th day of May, 2015, by and among REGENXBIO Inc., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto (the “Investors”), and the holders of Common Stock (as defined below) listed on Schedule B hereto (the “Common Holders” and together with the Investors, the “Holders”).
